Related stories
Faron Reports 85% Response Rate in Higher-Risk MDS Trial
Faron reported an 85% response rate in a frontline higher-risk MDS trial of a bexmarilimab combination.
M impact | EQUITY | Nov 04, 2026, 02:27 PM UTC
Adient Fiscal Q4 Adjusted Earnings Flat, Revenue Rises
M impact | EQUITY | Nov 04, 2026, 02:27 PM UTC
BioCryst Reports Higher Q3 Net Income and Revenue, Raises 2026 Revenue Guidance
BioCryst Pharmaceuticals reported increases in Q3 net income and revenue and raised its revenue guidance for 2026.
M impact | EQUITY | Nov 04, 2026, 02:27 PM UTC
Ford U.S. Electrified Vehicle Sales Fall 31.7% to 15,173 in October
L impact | EQUITY | Nov 04, 2026, 02:27 PM UTC
Shipping Corporation of India Reports Q2 Consolidated Net Profit of INR 5,777.6 Million
M impact | EQUITY | Nov 04, 2026, 02:27 PM UTC
Meta Sees Record Orders for First Eurobond Issue, Bloomberg Reports
Bloomberg reports that Meta received record orders for its first eurobond issue.
M impact | EQUITY | Nov 04, 2026, 02:26 PM UTC